Borawski, Jason and Gaither, Larry (2010) The evolution of RNAi technologies in the drug discovery business. European Pharmaceutical Review, 5. pp. 35-39. ISSN 1360-8606

Abstract

In the past decade, the pharmaceutical industry has exploited the naturally occurring cellular RNAi pathway to enhance drug discovery research. The RNAi pathway, triggered by dsRNA, selectively, although not always specifically, degrades mRNA leading to substantial decreases in post-transcriptional gene expression. Researchers have capitalized on this intrinsic pathway by synthesizing RNAi reagents to modify the expression of any desired gene. This review discusses how RNAi has contributed to the drug discovery process and the future possibilities of using RNAi in drug discovery and as a therapeutic modality itself.

Item Type:	Article
Additional Information:	archiving policy unclear
Keywords:	RNAi; drug discovery; shRNA; siRNA; screening
Date Deposited:	13 Oct 2015 13:15
Last Modified:	13 Oct 2015 13:15
URI:	https://oak.novartis.com/id/eprint/3693